Micro-Tech News

Nanwei Medicine (688029): Overseas expansion continues to promote focus on transforming value growth

Jul 12 07:36

Nanwei Medicine (688029): Traditional advantages, rapid growth of endoscopic consumables, accelerated maturation of visualization products

May 18 00:00

Nanwei Medical (688029): 24Q1 profit exceeded expectations and continued to reduce costs and increase efficiency

May 14 12:41

Nanwei Medical (688029): Net profit due to mother increased 47% in 2023, and overseas revenue grew rapidly

May 7 14:02

Nanwei Medical (688029) Comment: The 2023 and 2024Q1 results are in line with expectations, and I am optimistic that the company will reduce costs and increase efficiency and fully blossom overseas

Apr 29 00:00

Nanwei Medical (688029): Profit exceeded expectations and expanded to value growth

Apr 28 21:01

Nanwei Medical (688029) 2023 and 2024Q1 performance review: profit exceeded expectations, expanded on a larger scale and turned into value growth

Apr 28 00:00

Nanwei Medical (688029): 2023 results are in line with expectations, overseas business growth accelerates

Apr 27 13:26

Nanwei Medical (688029): 23-year results are in line with expectations, 24Q1 profit side is in line with expectations

Apr 27 00:00

Dongwu Securities released a research report on April 26 stating that it gave Nanwei Medicine (688029.SH) a purchase rating. The main reasons for the rating include: 1) steady growth in various domestic businesses in 2023; 2) the gradual opening up of ove

Zhitong FinanceApr 26 16:17

Nanwei Medicine (688029): Rapid growth in overseas revenue and continuous improvement in profits

Apr 26 13:31

Nanwei Medicine (688029): Steady domestic growth, continued high overseas growth

Apr 26 00:00

Nanwei Medical (688029): 23-year results are in line with expectations, and profit growth is steady

Feb 25 00:00

Nanwei Medical (688029): Rapid Q4 revenue growth performance is in line with expectations

Feb 23 16:31

Nanwei Medical (688029): 23-year performance report released, revenue grew rapidly in the fourth quarter

Feb 22 00:00

Nanwei Medicine (688029): Beijing-Tianjin-Hebei “3+N” Alliance Hemostasis Involvement Procurement Review: The proportion of hemostatic clips is gradually decreasing, and collection is expected to have limited impact

Nov 10, 2023 20:32

Southern Wei Medicine (688029): The proportion of hemostasis clips is gradually decreasing, and the expected impact of collection is limited

Nov 10, 2023 12:52

Nanwei Medicine (688029): Third quarter results continued to grow, overseas business continued to expand

Nov 7, 2023 15:46

Southern Wei Medicine (688029) 2023 Third Quarter Report Review: Sales Revenue Is Steady Growth, Profitability Continues to Improve

Nov 3, 2023 13:17

Nanwei Medicine (688029): High overseas growth+cost reduction and efficiency increase in third quarter results are in line with expectations

Oct 31, 2023 07:12